333 results
Page 4 of 17
8-K
EX-99.1
j4dbedbdewt
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
6qnfcstfq9zs c9qydkt
5 Aug 19
Cost Associated with Exit or Disposal Activities
8:55am
8-K
t39hlj
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
EX-99.1
frt6juoxxxsr74l
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
S-8
fd3e 3gkx
25 Jun 18
Registration of securities for employees
11:03am
8-K
EX-10.7
80jmufudh dnq
22 Jun 18
Departure of Directors or Certain Officers
4:02pm
8-K
EX-10.1
86qexnbe
22 Jun 18
Departure of Directors or Certain Officers
4:02pm
424B5
406c8j5rqdod
7 Jun 18
Prospectus supplement for primary offering
4:31pm
424B5
57dwxotlrdyzvd4 vkep
5 Jun 18
Prospectus supplement for primary offering
5:17pm
S-8
nwa dhb6su9ni9hxsnj
30 May 18
Registration of securities for employees
3:09pm